Therakos Inc, a pioneer for more than 20 years in immune cell therapy, has announced the receipt of a CE Mark in Europe for its THERAKOS(TM) CELLEX(TM) Photopheresis System. The THERAKOS CELLEX Photopheresis System is used for the treatment of immune-mediated diseases, such as acute or chronic graft-versus-host disease (GvHD) and cutaneous T-cell lymphoma (CTCL). The product offers state-of-the-art technology in a single, integrated, closed system device that allows a sole operator to customize a patient’s treatment and immediately adjust parameters to respond to changes in the patient’s condition.